Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/ki.2014.254 http://scihub22266oqcxt.onion/10.1038/ki.2014.254 C4281289!4281289 !25029429     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25029429 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Kidney+Int 2015 ; 87 (1 ): 169-75 Nephropedia Template TP {{tp|p=25029429 |t=2015. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial |pdf=|usr=}}{{25029429 }} gab.com Text Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial JO: Kidney Int http://www.kidney.de/pget.php?&tw=1&pmid=25029429 #FOAvip Apolipoprotein L1 gene (APOL1) G1 and G2 coding variants are strongly associated with chronic kidney disease (CKD) in African Americans (AAs). Here APOL1 association was tested with baseline estimated glomerular filtration rate (eGFR), urine albumin:creatinine ratio (UACR), and prevalent cardiovascular disease (CVD) in 2571 AAs from the Systolic Blood Pressure Intervention Trial (SPRINT), a trial assessing effects of systolic blood pressure reduction on renal and CVD outcomes. Logistic regression models that adjusted for potentially important confounders tested for association between APOL1 risk variants and baseline clinical CVD (myocardial infarction, coronary, or carotid artery revascularization) and CKD (eGFR under 60?ml/min per 1.73?m(2) and/or UACR over 30?mg/g). AA SPRINT participants were 45.3% female with a mean (median) age of 64.3 (63) years, mean arterial pressure 100.7 (100)?mm?Hg, eGFR 76.3 (77.1) ml/min per 1.73?m(2), and UACR 49.9 (9.2)?mg/g, and 8.2% had clinical CVD. APOL1 (recessive inheritance) was positively associated with CKD (odds ratio 1.37, 95% confidence interval 1.08-1.73) and log UACR estimated slope (?) 0.33) and negatively associated with eGFR (? -3.58), all significant. APOL1 risk variants were not significantly associated with prevalent CVD (1.02, 0.82-1.27). Thus, SPRINT data show that APOL1 risk variants are associated with mild CKD but not with prevalent CVD in AAs with a UACR under 1000?mg/g. Twit Text FOAVip Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial ????Kidney Int http://www.kidney.de/pget.php?&tw=1&pmid=25029429 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25029429 #FOAvip English Wikipedia <ref>{{Cite pmid|25029429 }}</ref> Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial #MMPMID25029429 Langefeld CD ; Divers J ; Pajewski NM ; Hawfield AT ; Reboussin DM ; Bild DE ; Kaysen GA ; Kimmel PL ; Raj DS ; Ricardo AC ; Wright JT Jr ; Sedor JR ; Rocco MV ; Freedman BI Kidney Int 2015[Jan]; 87 (1 ): 169-75 PMID25029429 show ga Apolipoprotein L1 gene (APOL1) G1 and G2 coding variants are strongly associated with chronic kidney disease (CKD) in African Americans (AAs). Here APOL1 association was tested with baseline estimated glomerular filtration rate (eGFR), urine albumin:creatinine ratio (UACR), and prevalent cardiovascular disease (CVD) in 2571 AAs from the Systolic Blood Pressure Intervention Trial (SPRINT), a trial assessing effects of systolic blood pressure reduction on renal and CVD outcomes. Logistic regression models that adjusted for potentially important confounders tested for association between APOL1 risk variants and baseline clinical CVD (myocardial infarction, coronary, or carotid artery revascularization) and CKD (eGFR under 60?ml/min per 1.73?m(2) and/or UACR over 30?mg/g). AA SPRINT participants were 45.3% female with a mean (median) age of 64.3 (63) years, mean arterial pressure 100.7 (100)?mm?Hg, eGFR 76.3 (77.1) ml/min per 1.73?m(2), and UACR 49.9 (9.2)?mg/g, and 8.2% had clinical CVD. APOL1 (recessive inheritance) was positively associated with CKD (odds ratio 1.37, 95% confidence interval 1.08-1.73) and log UACR estimated slope (?) 0.33) and negatively associated with eGFR (? -3.58), all significant. APOL1 risk variants were not significantly associated with prevalent CVD (1.02, 0.82-1.27). Thus, SPRINT data show that APOL1 risk variants are associated with mild CKD but not with prevalent CVD in AAs with a UACR under 1000?mg/g. |Apolipoprotein L1 [MESH] |Apolipoproteins/*genetics [MESH] |Black or African American/genetics [MESH] |Cardiovascular Diseases/*genetics [MESH] |Female [MESH] |Genetic Variation [MESH] |Humans [MESH] |Lipoproteins, HDL/*genetics [MESH] |Male [MESH] |Middle Aged [MESH]Apolipoprotein L1 gene variants associate with prevalent kidney but no(epmc).pdf DeepDyve Pubget Overpricing